Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.35

0.0%

Nov 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (1139)	12/8/2001 3:04:23 PM
From: Arthur Radley	Read Replies (1) of 1475

What is not mentioned in this CBSMarketWatch article about Barron's Alan Abelson in his interview with Larry Fienberg is the following comments.."the attempt by Ares-Serano to break Biogen's orphan drug status enjoyed by Avonex for MS and, most important perhaps, that its next big thing, Amevive for psoriasis, for which FDA approval seems imminent, doesn't lack for competition. Among the latter, if by no means the most prominent still formidable is BIOTRANSPLANT, that dandy little company we wrote admiringly about some months ago." marketwatch.com Also, it might be noted that in today's Investor's Business Daily, BTRN is sporting an accumulation rating of A+.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next